346 related articles for article (PubMed ID: 24097338)
1. EZH2 in normal and malignant hematopoiesis.
Lund K; Adams PD; Copland M
Leukemia; 2014 Jan; 28(1):44-9. PubMed ID: 24097338
[TBL] [Abstract][Full Text] [Related]
2. EZH2 in normal hematopoiesis and hematological malignancies.
Herviou L; Cavalli G; Cartron G; Klein B; Moreaux J
Oncotarget; 2016 Jan; 7(3):2284-96. PubMed ID: 26497210
[TBL] [Abstract][Full Text] [Related]
3. Multifaceted role of the polycomb-group gene EZH2 in hematological malignancies.
Sashida G; Iwama A
Int J Hematol; 2017 Jan; 105(1):23-30. PubMed ID: 27830540
[TBL] [Abstract][Full Text] [Related]
4. Oncogenic roles of enhancer of zeste homolog 1/2 in hematological malignancies.
Nakagawa M; Kitabayashi I
Cancer Sci; 2018 Aug; 109(8):2342-2348. PubMed ID: 29845708
[TBL] [Abstract][Full Text] [Related]
5. Ezh2 loss in hematopoietic stem cells predisposes mice to develop heterogeneous malignancies in an Ezh1-dependent manner.
Mochizuki-Kashio M; Aoyama K; Sashida G; Oshima M; Tomioka T; Muto T; Wang C; Iwama A
Blood; 2015 Sep; 126(10):1172-83. PubMed ID: 26219303
[TBL] [Abstract][Full Text] [Related]
6. Double sword role of EZH2 in leukemia.
Safaei S; Baradaran B; Hagh MF; Alivand MR; Talebi M; Gharibi T; Solali S
Biomed Pharmacother; 2018 Feb; 98():626-635. PubMed ID: 29289837
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of enhancer of zests homolog 2 in lymphoma.
Guo SQ; Zhang YZ
Chin Med J (Engl); 2012 Oct; 125(20):3735-9. PubMed ID: 23075734
[TBL] [Abstract][Full Text] [Related]
8. Targeting EZH2 and PRC2 dependence as novel anticancer therapy.
Xu B; Konze KD; Jin J; Wang GG
Exp Hematol; 2015 Aug; 43(8):698-712. PubMed ID: 26027790
[TBL] [Abstract][Full Text] [Related]
9. Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in myeloid malignancies.
Khan SN; Jankowska AM; Mahfouz R; Dunbar AJ; Sugimoto Y; Hosono N; Hu Z; Cheriyath V; Vatolin S; Przychodzen B; Reu FJ; Saunthararajah Y; O'Keefe C; Sekeres MA; List AF; Moliterno AR; McDevitt MA; Maciejewski JP; Makishima H
Leukemia; 2013 Jun; 27(6):1301-9. PubMed ID: 23486531
[TBL] [Abstract][Full Text] [Related]
10. Integrative Multi-Omics Analysis of Oncogenic EZH2 Mutants: From Epigenetic Reprogramming to Molecular Signatures.
Aldana J; Gardner ML; Freitas MA
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511137
[TBL] [Abstract][Full Text] [Related]
11. Tanshinone I, a new EZH2 inhibitor restricts normal and malignant hematopoiesis through upregulation of
Huang Y; Yu SH; Zhen WX; Cheng T; Wang D; Lin JB; Wu YH; Wang YF; Chen Y; Shu LP; Wang Y; Sun XJ; Zhou Y; Yang F; Hsu CH; Xu PF
Theranostics; 2021; 11(14):6891-6904. PubMed ID: 34093860
[No Abstract] [Full Text] [Related]
12. Loss of BAP1 function leads to EZH2-dependent transformation.
LaFave LM; Béguelin W; Koche R; Teater M; Spitzer B; Chramiec A; Papalexi E; Keller MD; Hricik T; Konstantinoff K; Micol JB; Durham B; Knutson SK; Campbell JE; Blum G; Shi X; Doud EH; Krivtsov AV; Chung YR; Khodos I; de Stanchina E; Ouerfelli O; Adusumilli PS; Thomas PM; Kelleher NL; Luo M; Keilhack H; Abdel-Wahab O; Melnick A; Armstrong SA; Levine RL
Nat Med; 2015 Nov; 21(11):1344-9. PubMed ID: 26437366
[TBL] [Abstract][Full Text] [Related]
13. Enhancer of zeste homolog 2 is overexpressed and contributes to epigenetic inactivation of p21 and phosphatase and tensin homolog in B-cell acute lymphoblastic leukemia.
Chen J; Li J; Han Q; Sun Z; Wang J; Wang S; Zhao RC
Exp Biol Med (Maywood); 2012 Sep; 237(9):1110-6. PubMed ID: 22956625
[TBL] [Abstract][Full Text] [Related]
14. Promotion of glioblastoma cell motility by enhancer of zeste homolog 2 (EZH2) is mediated by AXL receptor kinase.
Ott M; Litzenburger UM; Sahm F; Rauschenbach KJ; Tudoran R; Hartmann C; Marquez VE; von Deimling A; Wick W; Platten M
PLoS One; 2012; 7(10):e47663. PubMed ID: 23077658
[TBL] [Abstract][Full Text] [Related]
15. Targeting Epigenetic Crosstalk as a Therapeutic Strategy for EZH2-Aberrant Solid Tumors.
Huang X; Yan J; Zhang M; Wang Y; Chen Y; Fu X; Wei R; Zheng XL; Liu Z; Zhang X; Yang H; Hao B; Shen YY; Su Y; Cong X; Huang M; Tan M; Ding J; Geng M
Cell; 2018 Sep; 175(1):186-199.e19. PubMed ID: 30220457
[TBL] [Abstract][Full Text] [Related]
16. EZH2 is required for breast and pancreatic cancer stem cell maintenance and can be used as a functional cancer stem cell reporter.
van Vlerken LE; Kiefer CM; Morehouse C; Li Y; Groves C; Wilson SD; Yao Y; Hollingsworth RE; Hurt EM
Stem Cells Transl Med; 2013 Jan; 2(1):43-52. PubMed ID: 23283488
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic vulnerabilities of leukemia harboring inactivating EZH2 mutations.
Alqazzaz MA; Luciani GM; Vu V; Machado RAC; Szewczyk MM; Adamson EC; Cheon S; Li F; Arrowsmith CH; Minden MD; Barsyte-Lovejoy D
Exp Hematol; 2024 Feb; 130():104135. PubMed ID: 38072134
[TBL] [Abstract][Full Text] [Related]
18. Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells.
Kim E; Kim M; Woo DH; Shin Y; Shin J; Chang N; Oh YT; Kim H; Rheey J; Nakano I; Lee C; Joo KM; Rich JN; Nam DH; Lee J
Cancer Cell; 2013 Jun; 23(6):839-52. PubMed ID: 23684459
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic Control of Skeletal Development by the Histone Methyltransferase Ezh2.
Dudakovic A; Camilleri ET; Xu F; Riester SM; McGee-Lawrence ME; Bradley EW; Paradise CR; Lewallen EA; Thaler R; Deyle DR; Larson AN; Lewallen DG; Dietz AB; Stein GS; Montecino MA; Westendorf JJ; van Wijnen AJ
J Biol Chem; 2015 Nov; 290(46):27604-17. PubMed ID: 26424790
[TBL] [Abstract][Full Text] [Related]
20. EZH2 Inhibition Blocks Multiple Myeloma Cell Growth through Upregulation of Epithelial Tumor Suppressor Genes.
Hernando H; Gelato KA; Lesche R; Beckmann G; Koehr S; Otto S; Steigemann P; Stresemann C
Mol Cancer Ther; 2016 Feb; 15(2):287-98. PubMed ID: 26590165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]